close
News and Breakthroughs
How can I donate?
What events are happening?
Where does my money go?
See other stories

    “I speak about cancer. I ride my bike. I do these things because I want to change the story. I want a different ending.”

    In 2008, Patrick Sullivan lost his young son Finn to an extremely rare form of cancer, rhabdomyosarcoma. A few months later, he was approached by two close friends: “They told me about this fundraising bike ride to Seattle, the Ride to Conquer Cancer. They wanted to put a team in it – and do it in honour of Finn. That was the start of Team Finn.”

    Every member of Team Finn is inspired by a little boy who lived every moment of his short life to the fullest. Their distinctive pink jerseys read “Run. Jump. Bounce. Dance. Sing. Love. Smile. Ride,” words that celebrate Finn’s approach to every day.

    Finn showed how to live life with courage and joy, and his example has helped Team Finn achieve extraordinary success in raising funds for the BC Cancer Foundation. In just three years, they have raised over $1 million to support cancer research. As Finn’s father says, “Doctors couldn’t change Finn’s story. ‘Incurable’ was his ending. If I could change that for somebody else, then every moment of time is worth it.”

    Read Patrick Sullivan's Story
    Watch Patrick Sullivan's Story
    Watch video
    “I speak about cancer. I ride my bike. I do these things because I want to change the story. I want a different ending.”

    flyout blocks

    Read the latest news and research breakthroughs happening at the BC Cancer Agency

    flyout blocks

    Your donations support innovative cancer research and compassionate enhancements to patient care.

    flyout blocks

    Participate or donate to a fundraising event to support breakthrough cancer research in BC.

    flyout blocks

    See how your donations are being used to enable the great work at the BC Cancer Agency to continue.

    You are here

    Clinical study provides hope for women with ovarian cancer

    Dr. Karen Gelmon released promising clinical trial results in treating women with high-grade serous ovarian cancer with PARP inhibitors. Twenty-four per cent of the advanced ovarian cancer patients who do not have the BRCA hereditary cancer mutation responded to the treatment. As well, forty-one per cent of the patients with a BRCA gene mutation had their tumours shrink substantially. The results, published in The Lancet, have generated hope in the potential value of this treatment